Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep858 | Pituitary - Basic | ECE2016

Temozolomide has no direct effect on the normal and pathological hormone production in the anterior pituitary and in pituitary tumors

Korthower Daniela , Monteserin-Garcia Jose , Wu Yonghe , Stalla Johanna , Buchfelder Michael , Rachinger Walter , Stalla Gunter K. , Renner Ulrich

The chemotherapeutic agent temozolomide (TMZ) has been applied for the treatment of pituitary carcinomas, atypical pituitary adenomas and prolactinomas resistant to dopamine agonist treatment with considerable success. Both shrinkage of the tumors and a drop of excessive hormone production were observed in TMZ-responsive patients. In order to clarify whether the TMZ-induced suppression of hormone secretion was a consequence of tumor shrinkage or caused by direct effects on hor...

ea0041ep627 | Endocrine tumours and neoplasia | ECE2016

RSUME regulates tumorigenesis and metastasis in pancreatic neuroendocrine tumors

Wu Yonghe , Tedesco Lucas , Lucia Kristin , Schlitter Anna M , Esposito Irene , Auernhammer Christoph J , Theodoropoulou Marily , Arzt Eduardo , Stalla Gunter K , Renner Ulrich

The factors triggering pancreatic neuroendocrine tumor (PanNET) progression are largely unknown. Here we investigated the role and mechanisms of the sumoylation enhancing protein RSUME in PanNET tumorigenesis. Immunohistochemical studies showed that RSUME is strongly expressed in normal human pancreas, in particular in β-cells. RSUME expression is reduced in insulinomas and is nearly absent in other types of PanNETs suggesting a role in PanNET tumorigenesis. In human panc...